Episode
A conversation with Mr. JeVon McCormick, a man who found his name
We speak with Mr. JeVon McCormick, CEO of Scribe Media and author of Modern Leader. Mr. He helps individuals from ...
A conversation with Sam LaCrosse, a self-described nobody
A conversation with Sam LaCrosse, a self-described nobody We speak with Sam Lacrosse, author of Value Economics: The Study of ...
A conversation with Dr. Red Lawhern on the comments concerning the CDC opioid prescribing guidelines for chronic pain
We discuss trends in the comments that have appeared in response to the draft version of the updated clinical practice ...
A conversation with Dr. Thomas Kline & Jonelle Elgaway of the National Pain Council
Today we are here with Dr. Thomas Kline and Jonelle Elgaway, of the National Pain Council, a citizen's group with ...
A conversation with Mr. Adam Marcus, co-founder of Retraction Watch and editor for Primary Care at Medscape
We discuss the rise in retractions among academic publications, and the pandemic's impact on retractions in clinical journals over the ...
A conversation with Dr. John Whyte, Chief Medical Officer of WebMD and author of the new book, Take Control of Your Diabetes Risk
We discuss Dr. John Whyte's latest book, Take Control of Your Diabetes Risk, and reveal what it offers patients struggling ...
A conversation with Miss Tara Haelle, a health journalist and subject matter expert on vaccines
We discuss Miss Haelle's struggles to overcome vaccine misinformation during the pandemic. As a journalist, she often found herself at ...
A conversation with Miss Sandra Lamb, an award winning journalist and author
We discuss Miss Lamb’s experiences during the pandemic and glean her thoughts on how it affected the quality of writing ...
A conversation with Miss Andrea King Collier, author and award winning health journalist
We discuss her journalism as a writer and lived experiences as a patient during the pandemic, chronicling a timeline of ...
A conversation with Mr. John Tassoni, addiction policy expert and lobbyist at The Sentinel Group
We discuss addiction policies in Rhode Island and demonstrate how bureaucracies can influence the passing of addiction policy and law. ...
A conversation with Miss Leah Samuel, health and equity editor for The Conversation
We discuss health and equity in a post-pandemic world. While health and equity may be the future of medicine, its ...
A conversation with Mr. Ron Chapman, of Chapman Law Group, on Ruan v. United States
We discuss the oral arguments presented on March 1st in the seminal case, Ruan v. United States - arguably the ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex
-
Two Platforms, Two Theories of Change in Hospital Pricing
-
The Price Is Right, Theoretically: What Turquoise Health Actually Reveals About Hospital Markets
-
The Payer’s Dilemma: Choosing Between Negotiation Intelligence and Market Disclosure
-
Turquoise Health and the Cartography of Hidden Prices
